Stonepine Capital Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Stonepine Capital Management LLC
CRD #139891
SEC #801-136874
CIK #0001370042, 0001440771
AUM 181.0 M (2026-06-26)
Employees 4 (75% Investors, 0% Brokers)
Fees
Minimum
Phone541-647-5673
Address2900 NW Clearwater Drive
Bend, OR 97703
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
3502802101407002010201520212027
Fees and Compensation — Form ADV Part 2A (6/26/2026) [Brochure]
Item 5.        Fees and Compensation

Stonepine’s compensation is negotiable and varies, but typically it charges a 2% annual
management fee with respect to each investor in Stonepine Capital, payable in quarterly
installments at the beginning of each calendar quarter based on the net market value of each
investor’s capital account on that date. Stonepine also typically receives a performance-based
allocation with respect to each investor in Stonepine Capital equal to 20% of net profits (including
both realized and unrealized gains and losses) otherwise allocable to such investor. Performance
allocations are made with respect to each investor at the end of each calendar year (and on
withdrawals or redemptions with respect to the amount withdrawn or redeemed), and are typically
only applied to the portion of profits that exceed the cumulative losses previously allocated to that
investor in that year or in any subsequent year.

Stonepine may waive or reduce all or part of the management or performance-based allocations
with respect to any investor or Fund. For example, Stonepine has waived or reduced the

management fee and performance-based allocations for certain strategic investors in Stonepine
Capital and for certain employees and family members. In addition, an SPV may be subject to
lower management fees and performance-based allocations than Stonepine Capital. Please see
Item 6 below for additional information regarding Stonepine’s receipt of performance-based
allocations.

Stonepine typically deducts management fees and performance allocations directly from the
Funds.

Stonepine believes that its fees are competitive with fees charged by other investment advisers for
comparable services. Comparable services may be available, however, from other sources for
lower fees.

The disclosure in this Item 5, together with the disclosure in Item 12, allow a plan that is subject
to the Employee Retirement Income Security Act of 1974 and that invests in an investment limited
partnership of which Stonepine is general partner, to use the “alternative reporting option” to report
Stonepine’s compensation as “eligible indirect compensation” on the Schedule C of the plan’s
Form 5500 Annual Return/Report of Employee Benefit Plan.

Relationships with each Fund are terminable on expiration of the Fund’s term, its dissolution or
the termination of Stonepine as the investment adviser to the Fund. Generally, each investor may
withdraw from Stonepine Capital on specified prior written notice, on the last day of any calendar
quarter. If an investor in Stonepine Capital makes a withdrawal before the day preceding the first
anniversary of the capital contribution to which the withdrawn amount relates, that investor must
pay Stonepine Capital a withdrawal fee of 5% of the amount withdrawn (as detailed in Stonepine
Capital’s governing documents). An investor who withdraws from a Fund on a date other than the
last day of a quarter does not receive a refund of the management fee previously paid. Investors
in an SPV may be subject to more favorable liquidity provisions than Stonepine Capital.

Each Fund is responsible for its own costs and expenses, including trading costs and expenses
(such as brokerage commissions, expenses related to short sales, and clearing and settlement
charges), research expenses, ongoing legal, audit, bookkeeping fees and expenses, and the fees
and expenses charged by the Fund’s administrator and sub-administrator for their accounting,
bookkeeping and other services.

Stonepine allocates any expenses that relate to multiple Funds among all of those Funds as it deems
appropriate in its reasonable discretion.

Stonepine bears its own operating, general, administrative and overhead costs and expenses, other
than the expenses described in the preceding two paragraphs. All or part of these costs and
expenses may be paid, however, by securities brokerage firms that execute the Funds’ securities
trades, as discussed in Item 12 below.
Account Minimums and Types of Clients — Form ADV Part 2A (6/26/2026) [Brochure]
Item 7.        Types of Clients

Stonepine provides investment advice solely to investment funds. Investors in the Funds generally
are required to invest a minimum of $500,000, but Stonepine may waive, and has waived, this
minimum. Investors must be (i) “accredited investors” for purposes of Regulation D under the
Securities Act, and (ii) “qualified purchasers” as defined in Section 2(a)(51) of the Investment
Company Act.
Sector Form 13F Holdings Value ($M)
Verastem Inc 17.5
R&R Acquisition VI Inc 17.0
Oxygen Biotherapeutics Inc 15.6
Evolus Inc 9.0
Camp4 Therapeutics Corp 6.1
Nektar Therapeutics 6.1
Kempharm Inc 4.5
Access Pharmaceuticals Inc 3.8
Corbus Pharmaceuticals Holdings Inc 3.6
Establishment Labs Holdings Inc 3.2
View All
Holdings by Sector ($M)
3502802101407002014201820222027
Type Form D Funds Date Sold AUM
HF Metolius Capital LP [2017-03-30] 7.9 M 2.6 M
Filed 2018-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $18,645 · Net Assets Decline to Disclose
HF Tumalo Capital LP [2017-03-30] 7.6 M 2.5 M
Filed 2018-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $23,449 · Net Assets Decline to Disclose
HF Stonepine Capital LP 2015-03-24 181.0 M
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 1 181.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 1 181.0
By Discretionary
Discretionary 1 181.0
Non-Discretionary 0 0.0
Total 1 181.0
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 181.0
Total 1 181.0
Form D Directors Role # Filings # Firms 2011 - 2026
Timothy Lynch Executive Officer 7 2
Matt Carroll Executive Officer 4 2
Jon Plexico Executive Officer 3 2
Stonepine Capital Management LLC Executive Officer 3 2
Jeff Nunnenkamp Executive Officer 3 2
EDGAR Form CIK 2011 - 2026
3 [0001370042]
4 [0001370042]
SC 13D [0001370042]
SC 13G [0001370042]
13F-HR [0001440771]
3 [0001440771]
4 [0001440771]
SC 13G [0001440771]
Form 13D/13G Filer Form 13D/13G Subject Filed
Stonepine Capital Management LLC Pasithea Therapeutics Corp [2026-06-23]
Stonepine Capital Management LLC Azitra Inc [2026-06-22]
Stonepine Capital Management LLC Eloxx Pharmaceuticals Inc [2026-06-16]
Stonepine Capital Management LLC Sintx Technologies Inc [2026-06-09]
Stonepine Capital Management LLC Cellectar Biosciences Inc [2026-05-11]
Stonepine Capital Management LLC Curis Inc [2026-03-27]
Stonepine Capital Management LLC In8Bio Inc [2025-12-22]
Stonepine Capital Management LLC Quoin Pharmaceuticals Ltd [2025-12-16]
Stonepine Capital Management LLC CNS Pharmaceuticals Inc [2025-11-04]
Stonepine Capital Management LLC Verastem Inc [2025-08-06]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI213800AIP1E4A547KD30
Form 3/4/5 Subject 2011 - 2026
Stonepine Capital Management LLC
Quoin Pharmaceuticals Ltd
Chiasma Inc
Stonepine Capital LP
Novelion Therapeutics Inc
Lpath Inc
Societal CDMO Inc
Lynch Timothy P
Viveve Medical Inc
Plexico Jon M
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Chiasma Inc CHMA
Common Stock
2021-08-05 Disposed to issuer 6,770,000
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-12 Buy 1,000 $0.70 700
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-11 Buy 40 $0.69 28
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-10 Buy 5,202 $0.69 3,589
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-09 Buy 4,500 $0.70 3,150
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-06 Buy 40 $0.70 28
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-05 Buy 5,160 $0.70 3,612
Novelion Therapeutics Inc NVLNF
Common Stock
2019-11-22 Buy 89,845 $0.75 67,384
Novelion Therapeutics Inc NVLNF
Common Stock
2019-10-11 Buy 100,000 $0.65 65,000
Lpath Inc APEN
Warrant · derivative
2019-08-12 Other 1
Lpath Inc APEN
6.0% Convertible Debenture due 2024 · derivative
2019-08-12 Buy $2,775,000.00
Lpath Inc APEN
Common Stock
2019-08-12 Other 1,000,000
Lpath Inc APEN
Common Stock
2018-12-27 Sell 250,000 $3.00 750,000
Lpath Inc APEN
Common Stock
2018-12-26 Sell 500,000 $3.00 1,500,000
Lpath Inc APEN
Common Stock
2018-11-21 Buy 3,230 $3.61 11,660
Lpath Inc APEN
Common Stock
2018-11-19 Buy 54,200 $3.40 184,280
Lpath Inc APEN
Common Stock
2018-11-02 Buy 300,000 $5.00 1,500,000
Lpath Inc APEN
Common Stock
2018-01-03 Buy 6,339 $5.78 36,639
Lpath Inc APEN
Common Stock
2018-01-02 Buy 11,343 $5.73 64,995
Lpath Inc APEN
Common Stock
2017-12-29 Buy 5,163 $5.56 28,706
showing 20 of 43 most recent transactions
Comparable Firms State AUM
X Cubed Capital Management LLC
MN 184.0 M
Open Door Investment Management Ltd
CA 183.4 M
Smith Asset Management Group LP
TX 182.2 M
Emmett Investment Management LP
NY 181.6 M
Alpine Woods Capital Investors LLC
NY 180.6 M
2E Capital Partners LP
NY 180.0 M
Daventry Group LP
NY 179.9 M
Arc24 Management LP
NY 179.7 M
Gallo Partners LP
179.0 M
Candelo Capital Management LP
NY 178.1 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com